MILLENNIUM PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1993-01-01
- Employees
- 1K
- Market Cap
- -
A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-08-25
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT03261947
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇺🇸Siteman Cancer Center, Saint Louis, Missouri, United States
🇺🇸Sarah Cannon Research Institute Oncology Research Consortium, Denver, Colorado, United States
A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-05-31
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT03170882
- Locations
- 🇮🇹
Centro Di Riferimento Oncologico, Aviano, Italy
🇮🇹Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi, Bologna, Emilia-Romagna, Italy
🇨🇦Lakeridge Health Center, Ottawa, Ontario, Canada
A Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-906 in Healthy Participants
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2019-01-11
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03161405
- Locations
- 🇺🇸
Takeda Investigational Site, Lenexa, Kansas, United States
A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-02-20
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03057366
- Locations
- 🇭🇺
Magyar Honvédség Egészségügyi Központ Onkológiai osztály, Budapest, Hungary
🇭🇺PRA Magyarország Kft. Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Budapest, Hungary
A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)
- Conditions
- Interventions
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2019-05-24
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT02993783
- Locations
- 🇧🇪
UZ Leuven, Leuven, Belgium
🇫🇷Hopital Claude Huriez - CHU Lille, Lille cedex, Nord, France
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT02954406
- Locations
- 🇺🇸
West Virginia University, Morgantown, West Virginia, United States
🇺🇸Cedars-Sinai Medical Center (CSMC) - Samuel Oschin Comprehensive Cancer Institute, West Hollywood, California, United States
🇺🇸University of Arizona Cancer Center, Tucson, Tucson, Arizona, United States
A Study of Pevonedistat in Adult East Asian Participants
- First Posted Date
- 2016-05-25
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT02782468
- Locations
- 🇰🇷
The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of
🇰🇷Chonnam National University Hwasun Hospital, Jeonnam, Korea, Republic of
🇰🇷Severance Hospital Yonsei University Health System - PPDS, Seoul, Korea, Republic of
A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 241
- Registration Number
- NCT02725268
- Locations
- 🇺🇸
Florida Cancer Specialists, West Palm Beach, Florida, United States
🇺🇸University of Kansas Medical Center Research Institute, Inc., Westwood, Kansas, United States
🇺🇸University of Pittsburgh Medical Center Cancer Center at Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT02724020
- Locations
- 🇮🇹
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi, Bologna, Italy
🇮🇹Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy
🇫🇷Groupe Hospitalier Pitie-Salpetriere, Paris cedex 13, Paris, France
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
- Conditions
- Interventions
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT02723006
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States